News
Sarepta Tags DMD Gene Therapy Elevidys With Black Box Warning, Axes 500 Staff
Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta Therapeutics adds a black box warning to the gene therapy for acute liver injury and failure and parts with more than a third of employees.
The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...
The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
Investor's Business Daily on MSN9h
Sarepta Catapults 20% On Restructuring Plans In The Wake Of Two Patient DeathsSarepta stock catapulted Thursday after the company announced a restructuring that includes 500 layoffs in the wake of two patient deaths.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
MedPage Today on MSN9h
Duchenne Gene Therapy Will Undergo Changes After Patient DeathsAt the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...
This story was updated at 5:30 p.m. ET to include comment from an investor call. | Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback